# RAP1A

## Overview
RAP1A is a gene that encodes a small GTPase protein, which is a member of the RAS oncogene family. The RAP1A protein functions as a molecular switch, playing a pivotal role in various intracellular signaling pathways by cycling between active and inactive states. It is primarily involved in the regulation of cell adhesion, cell-cell junction stability, and integrin-mediated signaling, which are crucial for maintaining cellular architecture and function (Hattori2003Rap1; Caron2003Cellular). As a small GTPase, RAP1A is categorized as a signaling protein that influences processes such as cell migration, spreading, and morphology by modulating actin dynamics (Boettner2000The). The gene's expression and the protein's interactions have significant implications in various physiological and pathological contexts, including cardiovascular development and cancer progression (Liu2011A; Li2021MAPKRAP1A).

## Function
RAP1A, a member of the RAS oncogene family, encodes a small GTPase involved in various intracellular signaling pathways. It functions as a molecular switch, cycling between an active GTP-bound state and an inactive GDP-bound state, regulated by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs) (Hattori2003Rap1). In healthy human cells, RAP1A plays a crucial role in stabilizing cell-cell junctions, particularly in endothelial and epithelial tissues. It interacts with the KRIT1 protein, a specific effector, to maintain endothelial junctional integrity by suppressing Rho kinase signaling, which is essential for cardiovascular development (Liu2011A).

RAP1A is also involved in the formation of E-cadherin-based cell-cell contacts in epithelial cells. It enhances the recruitment of E-cadherin to contact sites, which is vital for stable cell-cell adhesion (Hogan2004Rap1). Additionally, RAP1A regulates integrin-mediated cell adhesion, influencing processes such as cell migration and spreading. It is active in the cytoplasm and at the plasma membrane, where it modulates actin dynamics and cell morphology (Boettner2000The; Caron2003Cellular). These functions underscore RAP1A's role in maintaining cellular architecture and signaling, contributing to normal cell growth and differentiation.

## Clinical Significance
Alterations in the expression of the RAP1A gene have significant clinical implications, particularly in hepatocellular carcinoma (HCC). Low expression of RAP1A is associated with advanced tumor grade, while higher expression is linked to poor overall survival in HCC patients, suggesting its potential role as a prognostic marker (Kumari2021Molecular). The MAPK-RAP1A signaling pathway is implicated in cancer progression, influencing cell proliferation, differentiation, and metastasis. This pathway is associated with favorable tumor-infiltrating immune cells and clinical prognosis in HCC, highlighting its importance in the tumor microenvironment (Li2021MAPKRAP1A).

RAP1A is also involved in the regulation of oncogenic Ras phenotype and Rho GTPase-mediated actin cytoskeleton, which are crucial for cancer cell motility and invasion (Li2021MAPKRAP1A). In addition, RAP1A expression is positively correlated with immune checkpoint B7 (CD80), indicating its role in modulating immune responses in HCC (Li2021MAPKRAP1A).

In cerebral cavernous malformations (CCM), the Krev-1/rap1a pathway, which includes RAP1A, is involved in angiogenesis and cerebrovascular disease. Mutations in the KRIT1 gene, a Krev-1/rap1a binding protein, are linked to CCM, emphasizing the pathway's significance in vascular development (Sahoo1999Mutations).

## Interactions
RAP1A, a member of the RAS oncogene family, is involved in various protein interactions that influence cellular processes. It specifically interacts with KRIT1, a Rap1-specific effector, in a GTP-dependent manner. This interaction is crucial for the stabilization of endothelial cell-cell junctions and cardiovascular development. KRIT1 binds to the switch 1 region of RAP1A, and this binding prevents KRIT1 from associating with microtubules, allowing it to localize to cell-cell junctions (Liu2011A).

RAP1A also interacts with the tumor suppressor RASSF1A, which is a novel effector of RAP1A. This interaction is regulated by the phosphorylation state of RASSF1A and the activation state of RAP1A. RASSF1A preferentially binds to the GTP-bound form of RAP1A, influencing microtubule organization and cellular signaling pathways (Verma2011The).

Additionally, RAP1A's interactions with the plasma membrane are influenced by its C-terminal anchors, which determine its lipid binding specificity. These interactions are crucial for its localization and function at the plasma membrane, where it forms distinct nanoclusters (Araya2024Differential).


## References


[1. (Sahoo1999Mutations) T. Sahoo, E. W. Johnson, J. W. Thomas, P. M. Kuehl, T. L. Jones, C. G. Dokken, J. W. Touchman, C. J. Gallione, S.-Q. Lee-Lin, B. Kosofsky, J. H. Kurth, D. N. Louis, G. Mettler, L. Morrison, A. Gil-Nagel, S. S. Rich, J. M. Zabramski, M. S. Boguski, E. Green, and D. A. Marchuk. Mutations in the gene encoding krit1, a krev-1/rap1a binding protein, cause cerebral cavernous malformations (ccm1). Human Molecular Genetics, 8(12):2325–2333, November 1999. URL: http://dx.doi.org/10.1093/hmg/8.12.2325, doi:10.1093/hmg/8.12.2325. This article has 300 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/8.12.2325)

[2. (Liu2011A) Jian J. Liu, Rebecca A. Stockton, Alexandre R. Gingras, Ararat J. Ablooglu, Jaewon Han, Andrey A. Bobkov, and Mark H. Ginsberg. A mechanism of rap1-induced stabilization of endothelial cell–cell junctions. Molecular Biology of the Cell, 22(14):2509–2519, July 2011. URL: http://dx.doi.org/10.1091/mbc.E11-02-0157, doi:10.1091/mbc.e11-02-0157. This article has 77 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1091/mbc.E11-02-0157)

[3. (Li2021MAPKRAP1A) Hailin Li, Guangyu Han, Xing Li, Bowen Li, Bo Wu, Hongyuan Jin, Lingli Wu, and Wei Wang. Mapk-rap1a signaling enriched in hepatocellular carcinoma is associated with favorable tumor-infiltrating immune cells and clinical prognosis. Frontiers in Oncology, June 2021. URL: http://dx.doi.org/10.3389/fonc.2021.649980, doi:10.3389/fonc.2021.649980. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2021.649980)

[4. (Kumari2021Molecular) Sarita Kumari, Mohit Arora, Jay Singh, Lokesh K. Kadian, Rajni Yadav, Shyam S. Chauhan, and Anita Chopra. Molecular associations and clinical significance of raps in hepatocellular carcinoma. Frontiers in Molecular Biosciences, June 2021. URL: http://dx.doi.org/10.3389/fmolb.2021.677979, doi:10.3389/fmolb.2021.677979. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fmolb.2021.677979)

[5. (Hogan2004Rap1) Catherine Hogan, Norberto Serpente, Patricia Cogram, Catherine Rose Hosking, Carl Uli Bialucha, Stephan Michael Feller, Vania M. M. Braga, Walter Birchmeier, and Yasuyuki Fujita. Rap1 regulates the formation of e-cadherin-based cell-cell contacts. Molecular and Cellular Biology, 24(15):6690–6700, August 2004. URL: http://dx.doi.org/10.1128/mcb.24.15.6690-6700.2004, doi:10.1128/mcb.24.15.6690-6700.2004. This article has 215 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.24.15.6690-6700.2004)

[6. (Hattori2003Rap1) M. Hattori. Rap1 gtpase: functions, regulation, and malignancy. Journal of Biochemistry, 134(4):479–484, October 2003. URL: http://dx.doi.org/10.1093/JB/MVG180, doi:10.1093/jb/mvg180. This article has 237 citations and is from a peer-reviewed journal.](https://doi.org/10.1093/JB/MVG180)

[7. (Verma2011The) Sunil K. Verma, Trivadi S. Ganesan, Uday Kishore, and Peter J. Parker. The tumor suppressor rassf1a is a novel effector of small g protein rap1a. Protein &amp; Cell, 2(3):237–249, March 2011. URL: http://dx.doi.org/10.1007/s13238-011-1028-z, doi:10.1007/s13238-011-1028-z. This article has 8 citations.](https://doi.org/10.1007/s13238-011-1028-z)

[8. (Araya2024Differential) Mussie K. Araya, Wei Chen, Yuepeng Ke, Yubin Zhou, Alemayehu A. Gorfe, John F. Hancock, and Junchen Liu. Differential lipid binding specificities of rap1a and rap1b are encoded by the amino acid sequence of the membrane anchors. Journal of the American Chemical Society, 146(29):19782–19791, July 2024. URL: http://dx.doi.org/10.1021/jacs.4c02183, doi:10.1021/jacs.4c02183. This article has 0 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1021/jacs.4c02183)

[9. (Boettner2000The) Benjamin Boettner, Eve-Ellen Govek, Justin Cross, and Linda Van Aelst. The junctional multidomain protein af-6 is a binding partner of the rap1a gtpase and associates with the actin cytoskeletal regulator profilin. Proceedings of the National Academy of Sciences, 97(16):9064–9069, August 2000. URL: http://dx.doi.org/10.1073/pnas.97.16.9064, doi:10.1073/pnas.97.16.9064. This article has 164 citations.](https://doi.org/10.1073/pnas.97.16.9064)

[10. (Caron2003Cellular) Emmanuelle Caron. Cellular functions of the rap1 gtp-binding protein: a pattern emerges. Journal of Cell Science, 116(3):435–440, February 2003. URL: http://dx.doi.org/10.1242/jcs.00238, doi:10.1242/jcs.00238. This article has 183 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1242/jcs.00238)